ERCC2 mutations have been associated with increased sensitivity to cisplatin-based chemotherapy in some bladder cancer cohorts, and functional analyses of selected ERCC2 mutations have demonstrated impaired NER activity. This evidence concerns the gene ERCC2 and urinary bladder carcinoma.